Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07828678
EARLY_PHASE1

PET/CT Imaging of GRPR Expression in Various Tumors

Sponsor: Jewish General Hospital

View on ClinicalTrials.gov

Summary

This open-label imaging study will evaluate \[⁶⁸Ga\]-LY4257529 PET/CT, a gastrin-releasing peptide receptor (GRPR)-targeted radiopharmaceutical, in patients with cancers known or suspected to express GRPR. Up to 60 participants will be enrolled in two cohorts: 30 patients with breast cancer and 30 patients with other selected malignancies, including prostate, ovarian, pancreatic, small-cell lung, head and neck squamous cell carcinoma, and other tumors with documented GRPR expression.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-11

Completion Date

2029-06

Last Updated

2026-09-18

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

GRPR PET/CT

\[⁶⁸Ga\]-LY4257529 is an investigational gastrin-releasing peptide receptor (GRPR)-targeted PET radiopharmaceutical. Participants will receive approximately 170 MBq ±20% (4.6 mCi ±20%) intravenously. PET/CT imaging will begin approximately 50-70 minutes after administration to evaluate GRPR-targeted tumor uptake and distribution.